Posts by Saul Richmond

Saul is PharmSource’s Director of Market Intelligence. He brings over 15 years of experience in market analysis, having worked in business intelligence roles at Evaluate Pharma, Cardinal Health (now Catalent) and Abbott Laboratories. Prior to that, he was a Post-doctoral fellow in Neuropharmacology at the Universities of Birmingham and Bristol.  Saul holds an MSc (Neuroscience) from the Institute of Psychiatry (King’s College London) and a D.Phil in Neuropharmacology from the University of Oxford.

VC Funding Only Bright Spot in Depressed Financing Picture

Following two record fundraising years is a tough act, and 2016 is shaping up to be somewhat anti-climactic. The data in Figure 1 (below) demonstrates just how quickly the environment has changed since the heady days of 2015. CDMOs and CROs need to be concerned about what it implies for demand for their services. Venture […]

Learn more

Identifying Atypical Opportunities using PharmSource Lead Sheet

Contract service providers that specialize in “non-standard” dose forms can use the PharmSource Lead Sheet’s detailed dosage form options to zero-in on opportunities appropriate to their capabilities. The system offers over 30 different dosage form categories, enabling you to shine the spotlight exactly where it suits your needs. Here’s an example of just four of […]

Learn more

Large Molecule API Outsourcing: Lots of sizzle but where’s the steak?

The rise of biologics should be positive for the CMO sector. With the cost of a commercial large molecule manufacturing facility north of $200m, the rationale to outsource API manufacture to a third party could be viewed as compelling. Actual experience indicates that it isn’t any more compelling than for any other manufacturing activity. PharmSource […]

Learn more

Pipeline Attrition: A Lead Sheet Perspective

If you want to increase your success rate, double your failure rate. — Thomas Watson, Jr. In clinical trials, not all failures are equal. Late stage attrition is far more costly than drug candidate terminations occurring earlier in the development process. Among many other things, the PharmSource Lead Sheet provides coverage of products that have […]

Learn more

Orphan Drugs a Growing Source of New Business Activity

In 2013, fully one third of approved New Molecular Entities (NMEs) were orphan drugs. Back in 1983, when Congress first established the orphan-drug designation, there was only one new such treatment per year across the industry; in the ensuing decades, that number has jumped to almost 200 per year. Today, nearly 33% of FDA-approved drugs […]

Learn more